IP Verse

Compositions And Methods Of Cellular Immunotherapy - EP3445407

The patent EP3445407 was granted to Cafa Therapeutics on Dec 14, 2022. The application was originally filed on Apr 21, 2017 under application number EP17833264A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3445407

CAFA THERAPEUTICS
Application Number
EP17833264A
Filing Date
Apr 21, 2017
Status
Granted And Under Opposition
Nov 11, 2022
Grant Date
Dec 14, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

MURGITROYDSep 13, 2023MURGITROYDADMISSIBLE
SOTIO BIOTECHSep 12, 2023MAIWALDADMISSIBLE

Patent Citations (12) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONCN104140974
INTERNATIONAL-SEARCH-REPORTCN101633693
INTERNATIONAL-SEARCH-REPORTCN104140974
INTERNATIONAL-SEARCH-REPORTUS2015093822
INTERNATIONAL-SEARCH-REPORTWO2016036973
INTERNATIONAL-SEARCH-REPORTWO2016049459
OPPOSITIONEP2995682
OPPOSITIONWO2012099973
OPPOSITIONWO2015172341
OPPOSITIONWO2017020812
OPPOSITIONWO2018018958
SEARCHEP2995682

Non-Patent Literature (NPL) Citations (38) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- CAMERON J TURTLE ET AL, "Anti-CD19 Chimeric Antigen Receptor-Modified T Cell Therapy for B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Fludarabine and Cyclophosphamide Lymphodepletion Improves In Vivo Expansion and Persistence of CAR-T Cells and Clinical Outcomes", INTERNET CITATION, ISSN 0006-4971, (20151203), URL: http://www.bloodjournal.org/content/126/23/184?sso-checked=true, (20171004), XP002774387-
OPPOSITION- Anonymous, "Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma", (20160823), pages 1 - 10, ClinicalTrials, URL: https://www.clinicaltrials.gov/study/NCT02876978?term=NCT02876978&rank=1&tab=history&a=1, (20240214), XP093131343-
OPPOSITION- Anonymous, "CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer", (20101011), pages 1 - 16, ClinicalTrials, URL: https://clinicaltrials.gov/study/NCT01218867?tab=history&a=37, (20230724), XP093131354-
OPPOSITION- Anonymous, "CART Cell Receptor lmmunotherapy Targeting Mesothelin for Patients With Metastatic Cancer", (20120424), pages 1 - 19, ClinicalTrials, URL: https://clinicaltrials.gov/study/NCT01583686?tab=history&a=1, (20240214), XP093131364-
OPPOSITION- Anonymous, "Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Turners (GAP) (GAP) ", (20161012), pages 1 - 13, ClinicalTrials, URL: https://www.clinicaltrials.gov/study/NCT02932956?term=NCT02932956, (20240214), XP093131357-
OPPOSITION- Anonymous, "Good Clinical Practice for Drug Trials", National Medical Products Administration (NMPA), (20030806), XP093192633-
OPPOSITION- Baylor College Of Medicine, "NCT00902044 Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma", ClinicalTrials.gov, NLM, (20151030), pages 1 - 17, ClinicalTrials.gov, URL: https://clinicaltrials.gov/study/NCT00902044?cond=NCT00902044&rank=1&tab=history&a=18, (20240212), XP093130063-
OPPOSITION- Carsgen Therapeutics Co., Ltd., "NCT02876978 Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma", ClinicalTrials.gov, NLM, (20160823), pages 1 - 11, ClinicalTrials.gov, URL: https://clinicaltrials.gov/study/NCT02876978?tab=history&a=1, (20240212), XP093130060-
OPPOSITION- M.D. Anderson Cancer Center, "NCT00338377 Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma", ClinicalTrials.gov, NLM, (20230809), pages 1 - 26, ClinicalTrials.gov, URL: https://clinicaltrials.gov/study/NCT00338377?cond=NCT00338377&rank=1&tab=history&a=67, (20240212), XP093130073-
OPPOSITION- Soranobu Ninomiya, Neeharika Narala, Leslie Huye, Shigeki Yagyu, Barbara Savoldo, Gianpietro Dotti, Helen E. Heslop, Malcolm K. Brenner, Cliona M. Rooney, Carlos A. Ramos, "Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs.", Blood, US , (20150618), vol. 125, no. 25, doi:10.1182/blood-2015-01-621474, ISSN 1528-0020, pages 3905 - 3916, XP002779636-
OPPOSITION- June Carl H., Maus Marcela V., Plesa Gabriela, Johnson Laura A., Zhao Yangbing, Levine Bruce L., Grupp Stephan A., Porter David L, "Engineered T cells for cancer therapy", Cancer immunology immunotherapy, Berlin/Heidelberg , (20140901), vol. 63, no. 9, doi:10.1007/s00262-014-1568-1, ISSN 0340-7004, pages 969 - 975, XP093164590
OPPOSITION- June Carl H., Maus Marcela V., Plesa Gabriela, Johnson Laura A., Zhao Yangbing, Levine Bruce L., Grupp Stephan A., Porter David L, "Engineered T cells for cancer therapy", Cancer immunology immunotherapy, Springer, Berlin/Heidelberg, Berlin/Heidelberg , (20140901), vol. 63, no. 9, doi:10.1007/s00262-014-1568-1, ISSN 0340-7004, pages 969 - 975, XP093164590
OPPOSITION- Kankeu Fonkoua Lionel, Sirpilla Olivia, Sakemura Reona, Siegler Elizabeth L., Kenderian Saad S., "CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities", Molecular Therapy - Oncolytics, Elsevier, (20220601), vol. 25, doi:10.1016/j.omto.2022.03.009, ISSN 2372-7705, pages 69 - 77, XP093192605
OPPOSITION- Richard A Morgan , James C Yang, Mio Kitano, Mark E Dudley, Carolyn M Laurencot, Steven A Rosenberg, "Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2", Molecular Therapy, US , (20100401), vol. 18, no. 4, doi:10.1038/mt.2010.24, ISSN 1525-0016, pages 843 - 851, XP055023624
OPPOSITION- Kheng Newick , Edmund Moon , Steven M Albelda, "Chimeric antigen receptor T-cell therapy for solid tumors", Molecular Therapy - Oncolytics, (20160101), vol. 3, doi:10.1038/mto.2016.6, ISSN 2372-7705, pages 1 - 6, XP055455162
OPPOSITION- Muranski Pawel; Boni Andrea; Wrzesinski Claudia; Citrin Deborah E; Rosenberg Steven A; Childs Richard; Restifo Nicholas P, "Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go?", NATURE CLINICAL PRACTICE ONCOLOGY, Nature Publishing Group., US, US , (20061201), vol. 3, no. 12, doi:10.1038/ncponc0666, ISSN 1743-4254, pages 668 - 681, XP037114967
OPPOSITION- Muranski Pawel, Boni Andrea, Wrzesinski Claudia, Citrin Deborah E, Rosenberg Steven A, Childs Richard, Restifo Nicholas P, "Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go?", Nature Clinical Practice Oncology, US , (20070117), vol. 3, no. 12, doi:10.1038/ncponc0666, ISSN 1743-4254, pages 1 - 21, XP093131345
OPPOSITION- Julie R Park, David L Digiusto, Marilyn Slovak, Christine Wright, Araceli Naranjo, Jamie Wagner, Hunsar B Meechoovet, Cherrilyn Bautista, Wen-Chung Chang, Julie R Ostberg, Michael C Jensen, "Adoptive Transfer of Chimeric Antigen Receptor Re-directed Cytolytic T Lymphocyte Clones in Patients with Neuroblastoma", Molecular Therapy, No longer published by Elsevier, (20070101), doi:10.1038/sj.mt.6300104, ISSN 15250016, XP055021897
OPPOSITION- Dudley Mark E., Wunderlich John R., Robbins Paul F., Yang James C., Hwu Patrick, Schwartzentruber Douglas J., Topalian Suzanne L., Sherry Richard, Restifo Nicholas P., Hubicki Amy M., Robinson Michael R., Raffeld Mark, Duray Paul, Seipp Claudia A., Rogers-Freezer Linda, Morton Kathleen E., Mavroukakis Sharon A., White Donald E., Rosenberg Steven A., "Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes", Science, US , (20021025), vol. 298, doi:10.1126/science.1076514, ISSN 0036-8075, pages 1 - 10, XP093131359
OPPOSITION- June Carl H., Riddell Stanley R., Schumacher Ton N., "Adoptive cellular therapy: A race to the finish line", SCIENCE TRANSLATIONAL MEDICINE, American Association for the Advancement of Science, (20150325), vol. 7, no. 280, doi:10.1126/scitranslmed.aaa3643, ISSN 1946-6234, page 280ps7, XP093182928
OPPOSITION- H. Gao, K. Li, H. Tu, X. Pan, H. Jiang, B. Shi, J. Kong, H. Wang, S. Yang, J. Gu, Z. Li, "Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular Carcinoma", Clinical Cancer Research, Association for Cancer Research, US, US, (20141215), vol. 20, no. 24, doi:10.1158/1078-0432.CCR-14-1170, ISSN 1078-0432, pages 6418 - 6428, XP055368289
OPPOSITION- H. Gao, K. Li, H. Tu, X. Pan, H. Jiang, B. Shi, J. Kong, H. Wang, S. Yang, J. Gu, Z. Li, "Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular Carcinoma", Clinical Cancer Research, US, (20141215), vol. 20, no. 24, doi:10.1158/1078-0432.CCR-14-1170, ISSN 1078-0432, pages 6418 - 6428, XP055368289
OPPOSITION- Shi Donghua, Shi Yaoping, Kaseb Ahmed O, Qi Xingxing, Zhang Yuan, Chi Jiachang, Lu Qing, Gao Huiping, Jiang Hua, Wang Huamao, Yuan Daijing, Ma Hong, Wang Hongyang, Li Zonghai, Zhai Bo, "Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials", Clinical cancer research, United States, United States , doi:10.1158/1078-0432.CCR-19-3259, pages 3979 - 3989, Clinical cancer research, URL: https://clincancerres.aacrjournals.org/content/clincanres/26/15/3979.full.pdf, (20210812), XP055831807
OPPOSITION- Phan Giao Q, Steven A Rosenberg, "Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy", CANCER CONTROL, Moffitt Cancer Center & Research Institute H Lee, US, US , (20131001), vol. 20, no. 4, doi:10.1177/107327481302000406, ISSN 1073-2748, pages 289 - 297, XP093130048
OPPOSITION- Turtle Cameron J; Hanafi Laila-Aicha; Berger Carolina; Sommermeyer Daniel; Pender Barbara; Robinson Emily M; Melville Katherine; Budiarto Tanya M; Steevens Natalia N; Chaney Colette; Cherian Sindhu; Wood Brent L; Soma Lorinda; Chen Xueyan; Heimfeld Shelly; Jensen Michael C; Riddell Stanley R.; Maloney David G, "Addition of Fludarabine to Cyclophosphamide Lymphodepletion Improves In Vivo Expansion of CD19 Chimeric Antigen Receptor-Modified T Cells and Clinical Outcome in Adults with B Cell Acute Lymphoblastic Leukemia", Blood, American Society of Hematology, US, US , (20151203), vol. 126, no. 23, doi:10.1182/blood.V126.23.3773.3773, ISSN 0006-4971, page 3773, XP086648592
OPPOSITION- Turtle Cameron J; Hanafi Laila-Aicha; Berger Carolina; Sommermeyer Daniel; Pender Barbara; Robinson Emily M; Melville Katherine; Budiarto Tanya M; Steevens Natalia N; Chaney Colette; Cherian Sindhu; Wood Brent L; Soma Lorinda; Chen Xueyan; Heimfeld Shelly; Jensen Michael C; Riddell Stanley R.; Maloney David G, "Addition of Fludarabine to Cyclophosphamide Lymphodepletion Improves In Vivo Expansion of CD19 Chimeric Antigen Receptor-Modified T Cells and Clinical Outcome in Adults with B Cell Acute Lymphoblastic Leukemia", Blood, US , (20151203), vol. 126, no. 23, doi:10.1182/blood.V126.23.3773.3773, ISSN 0006-4971, pages 1 - 3, XP086648592
OPPOSITION- Bot Adrian; Rossi John M.; Jiang Yizhou; Navale Lynn; Shen Yueh-wei; Sherman Marika; Mardiros Armen; Yoder Sean C.; Go William Y.; Rosenberg Steven A.; Wiezorek Jeff; Chang David D.; Kochenderfer James N.; Roberts Margo R., "Cyclophosphamide and Fludarabine Conditioning Chemotherapy Induces a Key Homeostatic Cytokine Profile in Patients Prior to CAR T Cell Therapy", Blood, US , (20151203), vol. 126, no. 23, doi:10.1182/blood.V126.23.4426.4426, ISSN 0006-4971, pages 1 - 3, XP086644971
OPPOSITION- Lana E Kandalaft;Daniel J Powell Jr;George Coukos, "A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer", Journal of Translational Medicine, (20120803), vol. 10, no. 1, doi:10.1186/1479-5876-10-157, ISSN 1479-5876, page 157, XP021116140
OPPOSITION- M. E. Dudley, Yang J. C., Sherry R., Hughes M. S., Royal R., Kammula U., Robbins P. F., Huang J., Citrin D. E., Leitman S. F., Wunderlich J., Restifo N. P., Thomasian A., Downey S. G., Smith F. O., Klapper J., Morton K., Laurencot C., White D. E., Rosenberg S. A., "Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens", Journal of Clinical Oncology, (20081110), vol. 26, no. 32, doi:10.1200/JCO.2008.16.5449, ISSN 0732-183X, pages 5233 - 5239, XP055057108
OPPOSITION- Baumhoer Daniel, Tornillo Luigi, Stadlmann Sylvia, Roncalli Massimo, Diamantis Eva Karamitopoulou, Terracciano Luigi M., "Glypican 3 Expression in Human Nonneoplastic, Preneoplastic, and Neoplastic Tissues : A Tissue Microarray Analysis of 4,387 Tissue Samples", AMERICAN JOURNAL OF CLINICAL PATHOLOGY, American Society for Clinical Pathology, US, US , (20080601), vol. 129, no. 6, doi:10.1309/HCQWPWD50XHD2DW6, ISSN 0002-9173, pages 899 - 906, XP093019428
OPPOSITION- Baumhoer Daniel, Tornillo Luigi, Stadlmann Sylvia, Roncalli Massimo, Diamantis Eva Karamitopoulou, Terracciano Luigi M., "Glypican 3 Expression in Human Nonneoplastic, Preneoplastic, and Neoplastic Tissues : A Tissue Microarray Analysis of 4,387 Tissue Samples", American Journal of Clinical Pathology, US , (20080601), vol. 129, no. 6, doi:10.1309/HCQWPWD50XHD2DW6, ISSN 0002-9173, pages 899 - 906, XP093019428
OPPOSITION- Leuci Valeria, Mesiano Giulia, Gammaitoni Loretta, Aglietta Massimo, Sangiolo Dario, "Genetically Redirected T Lymphocytes for Adoptive Immunotherapy of Solid Tumors", Current Gene Therapy, NL , (20140201), vol. 14, no. 1, doi:10.2174/1566523213666131223130353, ISSN 1566-5232, pages 52 - 62, XP093131371
OPPOSITION- Mitra Aroshi, Barua Amrita, Huang Luping, Ganguly Siddhartha, Feng Qin, He Bin, "From bench to bedside: the history and progress of CAR T cell therapy", Frontiers in Immunology, Frontiers Media, Lausanne, CH, Lausanne, CH , (20230515), vol. 14, doi:10.3389/fimmu.2023.1188049, ISSN 1664-3224, pages 01 - 14, XP093130051
OPPOSITION- Wu Qing, Zhou Yan, Fan Xin, Ma Huan, Gu Wenrui, Sun Fengjun, "Evaluation of nine formulas for estimating the body surface area of children with hematological malignancies", Frontiers in Pediatrics, Frontiers Research Foundation, CH, CH , vol. 10, doi:10.3389/fped.2022.989049, ISSN 2296-2360, XP093192627
OPPOSITION- David M. Barrett, Stephan A. Grupp, Carl H. June, "Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall Street", The Journal of Immunology, US , (20150801), vol. 195, no. 3, doi:10.4049/jimmunol.1500751, ISSN 0022-1767, pages 755 - 761, XP093164533
OPPOSITION- David M. Barrett, Stephan A. Grupp, Carl H. June, "Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall Street", The Journal of Immunology, Williams & Wilkins Co., US, US , (20150801), vol. 195, no. 3, doi:10.4049/jimmunol.1500751, ISSN 0022-1767, pages 755 - 761, XP093164533
SEARCH- KHENG NEWICK ET AL, "Chimeric antigen receptor T-cell therapy for solid tumors", MOLECULAR THERAPY - ONCOLYTICS, (20160101), vol. 3, doi:10.1038/mto.2016.6, ISSN 2372-7705, page 16006, XP055455162 [Y] 1-15 * the whole document *
SEARCH- KESANG LI ET AL, "Adoptive immunotherapy using T lymphocytes redirected to glypican-3 for the treatment of lung squamous cell carcinoma", ONCOTARGET, (20151214), vol. 7, no. 3, doi:10.18632/oncotarget.6595, XP055641064 [Y] 1-15 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents